Dr. Chris Martin is Chief Executive Officer of ADC Therapeutics having played an important role in the formation of ADC Therapeutics in 2012, and having served on its board of directors since its founding.
Previously Chris was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to its sale to MedImmune, the global biologics research and development arm of AstraZeneca, in October 2013, when he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. He led numerous Spirogen collaboration transactions, including agreements with two of the leading industry players in the antibody drug conjugate area, Genentech and Seattle Genetics.
Prior to Spirogen, Chris co-founded Xenva Ltd where he led investments in biotech and technology companies, and was also a co-founder of the Paras group in Europe. At Paras, he led the chemical, pharmaceutical and biotech practice specializing in valuing risky assets and environmental investments. Chris remains a consultant to Medimmune and is a non-executive director of RCM Technology Trust plc.
He is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.